GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...
Zacks Investment Research on MSN1d
GILD Data on Once-Yearly Lenacapavir for HIV Prevention PositiveGilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
Clinical Trials Arena on MSN1d
ViiV to trial twice-yearly HIV antibody dosing after Phase IIb successThe company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...
ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback